D

### Stolik:
I don't see how this little company can make its miracle drug, which needs to be administered every six months, profitable enough to beat my long position in GILD.

### Alex_D:
(see previous page and recent news). It has been making great strides with their 'no tolerance' HIV drug they announced about a month ago. It was successful in the trials and will be coming out very soon. The only bad thing is that there is only a 3 month window for them to start making this. They are also coming out with a drug for Hep-C which is even more prevalent in the world and has been a huge revenue generator for the industry. Also there are a couple other smaller drugs on the way that will keep the flow of money coming in as they are about to phase out of Hep-C treatments in the next couple years.

### Alex_D:
(see previous page and recent news). It has been making great strides with their 'no tolerance' HIV drug they announced about a month ago. It was successful in the trials and will be coming out very soon. The only bad thing is that there is only a 3 month window for them to start making this. They are also coming out with a drug for Hep-C which is even more prevalent in the world and has been a huge revenue generator for the industry. Also there are a couple other smaller drugs on the way that will keep the flow of money coming in as they are about to phase out of Hep-C treatments in the next couple years.

### Alex_D:
(see previous page and recent news). It has been making great strides with their 'no tolerance' HIV drug they announced about a month ago. It was successful in the trials and will be coming out very soon. The only bad thing is that there is only a 3 month window for them to start making this. They are also coming out with a drug for Hep-C which is even more prevalent in the world and has been a huge revenue generator for the industry. Also there are a couple other smaller drugs on the way that will keep the flow of money coming in as they are about to phase out of Hep-C treatments in the next couple years.

### Alex_D:
(see previous page and recent news). It has been making great strides with their 'no tolerance' HIV drug they announced about a month ago. It was successful in the trials and will be coming out very soon. The only bad thing is that there is only a 3 month window for them to start making this. They are also coming out with a drug for Hep-C which is even more prevalent in the world and has been a huge revenue Read from source...

.

### AGG:
AGG's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### SPLV:
SPLV's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### POPO:
POPO's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### ADMS:
ADMS's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### NVTA:
NVTA's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### CUTR:
CUTR's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### STAF:
STAF's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### UAA:
UAA's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### LPLA:
LPLA's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### APPF:
APPF's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### ING:
ING's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### INSG:
INSG's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### RICK:
RICK's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### INVH:
INVH's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### WIMI:
WIMI's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### CRSP:
CRSP's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### GCI:
GCI's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### GBSN:
GBSN's article story critics, highlighted inconsistencies, biases, irrational arguments, emotional behavior:.

### JNCE:
JNCE's article story critics, highlighted inconsistencies, biases

NEUTRAL
Subjects
Article Body
Market Cap (in billions):
Current Price:
52 Week High Price:
52 Week Low Price:
Article's Headline:
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
Article's Accuracy Rating: (0% - 100%) (%)
Editor's Note:
Tag: Neutral Article
Delivered To You FREE!
Get the latest scoop on companies that hit the sweet spot of Wall Street analysts with our free day by day filings newsletter.
Tags:
market news and data
See More From This Tag
Market Cap:
$303.67M
Current Price:
$2.01
52 Week High Price:
$5.32
52 Week Low Price:
$1.60
Editor's Note:
Negative Article
Published On:
Fri, 24 Mar 2023 19:28:00 +0000
Article Source:
- Benzinga
Like & Share Business News Readers!
Please Like & Share Business News Readers!
Benzinga.com |
New York, New York 10012, United States | (248) 200-4522
Legal Name: Benzinga.com | EIN: 38-2657455 | 10012, New York
Contact | Submit A Correction | Suggestion | Disclaimer
Follow Business News Readers
Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.

Forward.com on how to profit from Jerusalem in 2024, and by implication why its not worth buying companies with exposure to new global infrastructure projects with Biblical roots.,Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Be the first to comment!CommentsClose menuLoading...EarningsAnalyst RatingsOptionsDividendsIPOsdate▲▼ticker▲▼name▲▼Price Target▲▼Upside/Downside▲▼Recommendation▲▼Firm▲▼Click to see more Analyst Ratings updatesAnalyst CalendarJoin Benzinga Edge and unlock all the major upgrades, downgrades, and changes to the market's most accurate analysts.Click to JoinPosted In: BiotechLarge CapNewsPrice TargetSmall CapFDAFederal ReserveMarketsAnalyst RatingsTrading IdeasGeneralcontributorsBenzinga simplifies the market for smarter investingTrade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.Join Now: Free!Already a member?Sign in